PRA Health Sciences, Inc. (NASDAQ:PRAH) has been assigned an average rating of “Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $89.50.

Several equities research analysts recently issued reports on PRAH shares. Jefferies Group reissued a “buy” rating and issued a $95.00 target price on shares of PRA Health Sciences in a report on Thursday, October 26th. Zacks Investment Research downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. KeyCorp restated a “buy” rating and issued a $93.00 price target (up from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. Robert W. Baird set a $94.00 price target on PRA Health Sciences and gave the stock a “buy” rating in a research note on Friday, December 1st. Finally, Credit Suisse Group restated an “outperform” rating and issued a $90.00 price target (up from $84.00) on shares of PRA Health Sciences in a research note on Monday, October 16th.

PRA Health Sciences (PRAH) traded up $1.04 during trading on Friday, reaching $83.75. 503,499 shares of the company traded hands, compared to its average volume of 526,221. The stock has a market cap of $5,241.31, a price-to-earnings ratio of 30.41, a price-to-earnings-growth ratio of 1.43 and a beta of 0.40. PRA Health Sciences has a one year low of $53.47 and a one year high of $84.38. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million during the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 EPS. analysts predict that PRA Health Sciences will post 3.2 EPS for the current fiscal year.

In other news, Director Matthew P. Young sold 5,115 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Carroll Financial Associates Inc. boosted its position in shares of PRA Health Sciences by 127.4% during the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 790 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of PRA Health Sciences by 12.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 160 shares during the last quarter. Comerica Bank bought a new position in shares of PRA Health Sciences during the 3rd quarter valued at approximately $214,000. Trustmark National Bank Trust Department bought a new position in shares of PRA Health Sciences during the 2nd quarter valued at approximately $225,000. Finally, Aperio Group LLC bought a new position in shares of PRA Health Sciences during the 2nd quarter valued at approximately $233,000. Hedge funds and other institutional investors own 98.49% of the company’s stock.

WARNING: “Analysts Set PRA Health Sciences, Inc. (PRAH) Target Price at $89.09” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/analysts-set-pra-health-sciences-inc-prah-target-price-at-89-09/1758333.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.